Trials / Recruiting
RecruitingNCT06013995
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986326 | Specified dose on specified days |
| OTHER | Placebo for BMS-986326 | Specified dose on specified days |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2026-04-08
- Completion
- 2026-04-08
- First posted
- 2023-08-28
- Last updated
- 2026-04-01
Locations
27 sites across 9 countries: United States, Argentina, Bulgaria, Germany, Mexico, Netherlands, Poland, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06013995. Inclusion in this directory is not an endorsement.